Overall, these results suggest that AhR may serve as a biomarker for poor prognosis in bladder cancer, and that 3‐IAA may modulate AhR signaling by directly binding to the receptor, thereby regulating cellular transcriptional activity and physiological responses. This evidence concerns the gene AHR and urinary bladder cancer.